Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 8/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MDH2 | P40926 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31399090 | 1.00 | AHR (0.46) | AHRCMA1PLK1CCNB2CDK1 | |
| SCHEMBL771568 | 0.86 | KDM4E (0.43) | AHRCMA1CCNB2CDK1CCNB1 | |
| SCHEMBL29783128 | 0.86 | PLK1 (0.40) | PLK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL25556303 | 0.86 | PLK1 (0.40) | PLK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL25556335 | 0.85 | TGM2 (0.41) | PLK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL25556641 | 0.85 | CMA1 (0.46) | AHRCMA1CCNB2CDK1CCNB1 | |
| SCHEMBL29783088 | 0.85 | PDE3B (0.50) | PLK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL25556267 | 0.85 | PDE3B (0.50) | PLK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL29783105 | 0.81 | CCNB2 (0.47) | PLK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL25556438 | 0.81 | CCNB2 (0.47) | PLK1CCNB2CDK1CCNB1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088420-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-05-25 | — | — | WO | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-7041662-B2 | Substituted benzo [b] azepin-2-one compounds | GRUNENTHAL GMBH (DE) | 2006-05-09 | — | — | US | disclosed |
| US-20040224980-A1 | Substituted 1H-quinolin-2-one compounds | GRUNENTHAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040224938-A1 | Substituted benzo [b] azepin-2-one compounds | GRUNENTHAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | AHR 2775/4885CMA1 1440/4885PLK1 1122/4885 |
| US-20040224938-A1 | Substituted benzo [b] azepin-2-one compounds | GABARAPL2, GABBR2, GABBR1 | AHR 2796/4885CMA1 338/4885PLK1 3379/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | AHR 2775/4885CMA1 1440/4885PLK1 1122/4885 |
| US-20040224980-A1 | Substituted 1H-quinolin-2-one compounds | NQO1, QARS1, QDPR | AHR 3560/4885CMA1 164/4885PLK1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.